Skip to main content
SpringerLink
Log in

Using a single inhaler device containing an inhaled corticosteroid plus a long-acting β-adrenoceptor agonist is a practical approach in patients with moderate to severe asthma

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. American Thoracic Society (ATS). Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136(1): 225–44

    Article  Google Scholar 

  2. Farber HJ, Boyette M. Control your child’s asthma: a breakthrough program for the treatment and management of childhood asthma. New York (NY): Henry Holt, 2001

    Google Scholar 

  3. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma: update on selected topics 2002. Bethesda (MD): US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, 2003 Jun. NIH publication no. 02-5074

    Google Scholar 

  4. Farber HJ, Glauber J. Combination therapy for asthma perspectives of the patient, provider, and payer. Dis Manage Health Outcomes 2006; 14(6): 353–68

    Article  CAS  Google Scholar 

  5. Martinez FD. Safety of long-acting beta-agonists: an urgent need to clear the air. N Engl J Med 2005 Dec 22; 353(25): 2637–9

    Article  PubMed  CAS  Google Scholar 

  6. Wooltorton E. Long acting β2-agonists in asthma: safety concerns. CMAJ 2005 Oct 25; 173(9): 1030–1

    Article  PubMed  Google Scholar 

  7. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multi-center Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006 Jan; 129(1): 15–26

    Article  PubMed  CAS  Google Scholar 

  8. Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006 Jun 20; 144(12): 904–12

    PubMed  CAS  Google Scholar 

  9. D’Urzo AD. Inhaled glucocorticosteroid and long-acting β2-adrenoceptor agonist single-inhaler combination for both maintenance and rescue therapy: a paradigm shift in asthma management. Treat Respir Med 2006; 5(6): 385–91

    Article  PubMed  Google Scholar 

  10. Palmqvist M, Arvidsson P, Beckman O, et al. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther 2001; 14(1): 29–34

    Article  PubMed  CAS  Google Scholar 

  11. Palmqvist M, Persson G, Lazer L, et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997 Nov; 10(11): 2484–9

    Article  PubMed  CAS  Google Scholar 

  12. Caress AL, Beaver K, Luker K, et al. Involvement in treatment decisions: what do adults with asthma want and what do they get? Results of a cross sectional survey. Thorax 2005 Mar; 60(3): 199–205

    Article  PubMed  Google Scholar 

  13. O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001 Oct 15; 164 (8 Pt 1): 1392–7

    PubMed  Google Scholar 

  14. Gendo K, Sullivan SD, Lozano P, et al. Resource costs for asthma related care among pediatric patients in managed care. Ann Allergy Asthma Immunol 2003 Sep; 91(3): 251–7

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Using a single inhaler device containing an inhaled corticosteroid plus a long-acting β-adrenoceptor agonist is a practical approach in patients with moderate to severe asthma. Drugs Ther. Perspect 24, 9–11 (2008). https://doi.org/10.2165/00042310-200824030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200824030-00003

Keywords

Search

Navigation